Comparison of laser epithelial keratomileusis with and without mitomycin C for wavefront customized surface ablations - PubMed
Randomized Controlled Trial
. 2007 Nov;23(9 Suppl):S1021-8.
doi: 10.3928/1081-597X-20071102-08.
Affiliations
- PMID: 18047001
- DOI: 10.3928/1081-597X-20071102-08
Randomized Controlled Trial
Comparison of laser epithelial keratomileusis with and without mitomycin C for wavefront customized surface ablations
Eliane Mayumi Nakano et al. J Refract Surg. 2007 Nov.
Abstract
Purpose: To investigate the efficacy of mitomycin C (MMC) in preventing haze formation in surface wavefront customized ablations with successful refractive treatment (laser epithelial keratomileusis [LASEK]) and to evaluate the safety of this technique on corneal stroma and endothelium.
Methods: This study was a prospective, double-masked, randomized clinical trial involving 52 eyes (30 placebo and 22 MMC) of 26 patients. The manifest refractive spherical equivalent (MRSE), best spectacle-corrected visual acuity, uncorrected visual acuity, corneal pachymetry, topography, aberrometry, endothelial specular microscopy, contrast sensitivity, corneal confocal microscopy, and complaints of pain via a subjective questionnaire were recorded preoperatively and 90 days postoperatively.
Results: The mean MRSE at 90 days postoperatively was -0.56 diopters (D) (-4.95 +/- 1.85 D, range: -8.00 to -1.62 D) for the MMC group and -0.49 D (-4.51 +/- 1.81 D, range: -7.75 to -2.25 D) for the placebo group. Higher order aberrations were similar between the placebo and MMC groups 90 days postoperatively (0.538 +/- 0.228 microm and 0.478 +/- 0.134 microm, respectively). Analysis of the endothelial cell count indicated a statistically significant decrease in endothelial cell density (P = .017) after LASEK, independent of MMC use.
Conclusions: The predictability of the final target refraction, induction of high order aberrations, and improvement in contrast sensitivity proved that the use of MMC was equally safe when compared to procedures that did not use MMC. In addition, the procedure was efficient in the prevention of corneal haze.
Similar articles
-
Laser epithelial keratomileusis with mitomycin C: indications and limits.
Camellin M. Camellin M. J Refract Surg. 2004 Sep-Oct;20(5 Suppl):S693-8. doi: 10.3928/1081-597X-20040903-13. J Refract Surg. 2004. PMID: 15521270
-
Hofmeister EM, Bishop FM, Kaupp SE, Schallhorn SC. Hofmeister EM, et al. J Cataract Refract Surg. 2013 Sep;39(9):1358-65. doi: 10.1016/j.jcrs.2013.03.029. Epub 2013 Jul 3. J Cataract Refract Surg. 2013. PMID: 23830559 Clinical Trial.
-
Rajan MS, O'Brart DP, Patel P, Falcon MG, Marshall J. Rajan MS, et al. J Cataract Refract Surg. 2006 Jun;32(6):949-57. doi: 10.1016/j.jcrs.2006.02.036. J Cataract Refract Surg. 2006. PMID: 16814052
-
Kuryan J, Cheema A, Chuck RS. Kuryan J, et al. Cochrane Database Syst Rev. 2017 Feb 15;2(2):CD011080. doi: 10.1002/14651858.CD011080.pub2. Cochrane Database Syst Rev. 2017. PMID: 28197998 Free PMC article. Review.
-
Kottler UB, Dick HB. Kottler UB, et al. Klin Monbl Augenheilkd. 2005 Jun;222(6):499-504. doi: 10.1055/s-2005-857942. Klin Monbl Augenheilkd. 2005. PMID: 15973629 Review. German.
Cited by
-
Atorvastatin Can Modulate DNA Damage Repair in Endothelial Cells Exposed to Mitomycin C.
Sinitsky M, Asanov M, Sinitskaya A, Shishkova D, Khutornaya M, Minina V, Ponasenko A. Sinitsky M, et al. Int J Mol Sci. 2023 Apr 5;24(7):6783. doi: 10.3390/ijms24076783. Int J Mol Sci. 2023. PMID: 37047754 Free PMC article.
-
Sinitsky M, Repkin E, Sinitskaya A, Markova V, Shishkova D, Barbarash O. Sinitsky M, et al. Int J Mol Sci. 2024 Apr 5;25(7):4044. doi: 10.3390/ijms25074044. Int J Mol Sci. 2024. PMID: 38612854 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources